Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will ...
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc.
Pitt Street Research and Euroz Hartleys have released research notes on Dimerix highlighting upside potential as progresses ...
An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its ...
Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Johnson & Johnson will present at the Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27th, 2026.
Strand Therapeutics, a clinical-stage biotechnology company pioneering programmable mRNA medicines, today announced it will present preclinical data from its in vivo CAR-T program at the 2026 American ...
In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Ardelyx, with a price target of $16.00.
The Summers Value Fund LP returned 6.7% net in 2025, trailing Russell 2000 Index ETF, which returned 12.7%, and Russell 2000 ...
Investor's Business Daily on MSN
Royalty powerhouse: Ligand and Xoma unite in $739 million deal
Ligand Pharmaceuticals snatched up Xoma Royalty in a deal worth $739 million, the companies said Monday as both biotech ...
"AstraZeneca to seek accelerated approval of Ultomirisin in IgAN on Phase III data" was originally created and published by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results